Ōgaki

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Fatty liver disease (MASLD/MASH)2 trials
• Liver cirrhosis2 trials
• Multiple myeloma1 trial

Phase

• Phase 33 trials

Status

• Recruiting2 trials
• Active, not recruiting1 trial

Lead sponsor

• GlaxoSmithKline3 trials

Running trials

• Recruiting

  A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

  NCT07704892· Phase 3· GlaxoSmithKline· Source

  Contact: Hidenori Toyoda (principal investigator)

• Recruiting

  A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

  NCT07701993· Phase 3· GlaxoSmithKline· Source

  Contact: Hidenori Toyoda (principal investigator)

• Active, not recruiting

  Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

  NCT06868667· Phase 3· GlaxoSmithKline· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)2 recruiting
• Liver cirrhosis2 recruiting